StreetInsider.com News Articles

Topicus.com Inc. Announces Release Date for Third Quarter Results

Fri, 16 Oct 2026 16:57:00 -0400

TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2026.

The Company’s quarterly results will be disseminated via press release and made available on the Company’s website (www.topicus.com) and the SEDAR website (www.sedarplus.ca), after markets close on Wednesday, November 4, 2026.

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI". Topicus acquires, manages and builds vertical market software businesses.
Contact:

Topicus.com Inc. Announces Release Date for Third Quarter Results

Fri, 16 Oct 2026 16:57:00 -0400

TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2026.

About Topicus.com Inc.

Topicus’ subordinate voting shares are listed on the Toronto Venture Stock Exchange under the symbol "TOI". Topicus acquires, manages and builds vertical market software businesses.
Contact:

Topicus.com names Ramon Zanders as CEO, replacing van Poelje

Mon, 14 Sep 2026 16:32:23 -0400

Topicus.com Inc. (TSX-V: TOI) announced that Robin van Poelje will retire as Chief Executive Officer on Oct. 1, 2026, for personal reasons, with Ramon Zanders named as his successor.

Zanders currently serves as Group CEO of the Total Specific Solutions Blue operating group within Topicus and will retain that role alongside his new responsibilities as CEO. He has also been appointed to the Topicus Board of Directors. Van Poelje will remain on the board as Chairman following his retirement.

Mark Miller, President of Constellation Software and a director of Topicus.com Cooperatief U.A., said, "Robin has led Topicus, and its predecessor TSS, with

Topicus.com names Ramon Zanders as CEO, replacing van Poelje

Mon, 14 Sep 2026 16:32:23 -0400

Topicus.com Inc. (TSX-V: TOI) announced that Robin van Poelje will retire as Chief Executive Officer on Oct. 1, 2026, for personal reasons, with Ramon Zanders named as his successor.

Mark Miller, President of Constellation Software and a director of Topicus.com Cooperatief U.A., said, "Robin has led Topicus, and its predecessor TSS, with

Robin van Poelje to Retire as CEO of Topicus.com Inc. on October 1, 2026; Board Names Ramon Zanders as his Successor

Mon, 14 Sep 2026 16:32:00 -0400

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. ("Topicus") announced today Robin van Poelje’s decision to retire from his position as Chief Executive Officer of Topicus for personal reasons. Ramon Zanders, currently the Group CEO of the Total Speciﬁc Solutions Blue operating group within Topicus, has been appointed Chief Executive Officer of Topicus by the Topicus Board of Directors. These changes will be effective October 1, 2026. Following his retirement as Chief Executive Officer, Mr. van Poelje will continue as a Director and Chairman of the Board of Topicus.

Mark Milller, President of Constellation

Robin van Poelje to Retire as CEO of Topicus.com Inc. on October 1, 2026; Board Names Ramon Zanders as his Successor

Mon, 14 Sep 2026 16:32:00 -0400

Mark Milller, President of Constellation

Form 4 Starling Oncology, Inc. For: Aug 21 Filed by: Hively Brad

Mon, 24 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26969077.html

Form 4 Starling Oncology, Inc. For: Aug 21 Filed by: Hively Brad

Mon, 24 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26969077.html

Form 8-K Starling Oncology, Inc. For: Aug 20

Fri, 21 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260821/26962534.html

Form 8-K Starling Oncology, Inc. For: Aug 20

Fri, 21 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260821/26962534.html

Form 8-K Starling Oncology, Inc. For: Aug 20

Fri, 21 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260821/26962534.html

Form 144 Starling Oncology, Inc. Filed by: Hively Brad

Fri, 21 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260821/26961897.html

Form 144 Starling Oncology, Inc. Filed by: Hively Brad

Fri, 21 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260821/26961897.html

Form 144 Starling Oncology, Inc. Filed by: Hively Brad

Fri, 21 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260821/26961897.html

Form 4 Starling Oncology, Inc. For: Aug 13 Filed by: Chernett Jorey

Mon, 17 Aug 2026 10:13:00 -0400

si-local-file:///var/storage/secattach/20260817/26936212.html

Form 4 Starling Oncology, Inc. For: Aug 13 Filed by: Chernett Jorey

Mon, 17 Aug 2026 10:13:00 -0400

si-local-file:///var/storage/secattach/20260817/26936212.html

Form 10-Q Starling Oncology, Inc. For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884895.html

Form 10-Q Starling Oncology, Inc. For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884895.html

Form 10-Q Starling Oncology, Inc. For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884895.html

Form 8-K Starling Oncology, Inc. For: Aug 06

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884805.html

Form 8-K Starling Oncology, Inc. For: Aug 06

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884805.html

Form 8-K Starling Oncology, Inc. For: Aug 06

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884805.html

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the